View ValuationThis company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsKaro Pharma 将来の成長Future 基準チェック /06主要情報n/a収益成長率n/aEPS成長率Pharmaceuticals 収益成長10.4%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesReported Earnings • Feb 26Full year 2021 earnings: EPS in line with expectations, revenues disappointFull year 2021 results: kr0.08 loss per share (down from kr0.37 profit in FY 2020). Revenue: kr2.96b (up 2.7% from FY 2020). Net loss: kr17.5m (down 121% from profit in FY 2020). Revenue missed analyst estimates by 2.3%. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 131 percentage points per year, which is a significant difference in performance.Reported Earnings • Oct 30Third quarter 2021 earnings released: EPS kr0.26 (vs kr0.013 loss in 3Q 2020)The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: kr738.5m (up 8.7% from 3Q 2020). Net income: kr59.0m (up kr61.8m from 3Q 2020). Profit margin: 8.0% (up from net loss in 3Q 2020). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 128 percentage points per year, which is a significant difference in performance.Reported Earnings • Jul 23Second quarter 2021 earnings released: kr0.095 loss per share (vs kr0.11 profit in 2Q 2020)The company reported a soft second quarter result with weaker earnings and weaker control over costs, although revenues improved. Second quarter 2021 results: Revenue: kr747.9m (up 8.6% from 2Q 2020). Net loss: kr21.4m (down 184% from profit in 2Q 2020). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 127 percentage points per year, which is a significant difference in performance.Executive Departure • Apr 27Independent Chairman of the Board Bo Hansen has left the companyOn the 21st of April, Bo Hansen's tenure as Independent Chairman of the Board ended after 2.2 years in the role. We don't have any record of a personal shareholding under Bo's name. A total of 2 executives have left over the last 12 months.Reported Earnings • Apr 24First quarter 2021 earnings released: EPS kr0.24 (vs kr0.39 in 1Q 2020)The company reported a poor first quarter result with weaker earnings, revenues and profit margins. First quarter 2021 results: Revenue: kr713.0m (down 10% from 1Q 2020). Net income: kr53.3m (down 39% from 1Q 2020). Profit margin: 7.5% (down from 11% in 1Q 2020). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 103 percentage points per year, which is a significant difference in performance.Reported Earnings • Apr 01Full year 2020 earnings released: EPS kr0.37 (vs kr0.051 in FY 2019)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: kr2.88b (up 52% from FY 2019). Net income: kr82.0m (up kr73.2m from FY 2019). Profit margin: 2.8% (up from 0.5% in FY 2019). Over the last 3 years on average, earnings per share has fallen by 59% per year but the company’s share price has increased by 17% per year, which means it is well ahead of earnings.Reported Earnings • Feb 20Full year 2020 earnings released: EPS kr0.37 (vs kr0.051 in FY 2019)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: kr2.88b (up 52% from FY 2019). Net income: kr82.0m (up kr73.2m from FY 2019). Profit margin: 2.8% (up from 0.5% in FY 2019). Over the last 3 years on average, earnings per share has fallen by 59% per year but the company’s share price has increased by 16% per year, which means it is well ahead of earnings.Is New 90 Day High Low • Feb 11New 90-day low: kr47.48The company is down 25% from its price of kr62.90 on 13 November 2020. The British market is up 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 13% over the same period.Is New 90 Day High Low • Jan 26New 90-day low: kr48.75The company is down 26% from its price of kr66.20 on 28 October 2020. The British market is up 16% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 1.0% over the same period.Is New 90 Day High Low • Jan 07New 90-day low: kr51.15The company is down 27% from its price of kr70.50 on 09 October 2020. The British market is up 14% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 6.0% over the same period.Is New 90 Day High Low • Dec 18New 90-day low: kr56.30The company is down 23% from its price of kr73.10 on 18 September 2020. The British market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 12% over the same period.Is New 90 Day High Low • Nov 26New 90-day low: kr61.20The company is down 1.0% from its price of kr61.90 on 28 August 2020. The British market is up 7.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Pharmaceuticals industry, which is down 5.0% over the same period.Reported Earnings • Oct 30Third quarter earnings releasedOver the last 12 months the company has reported total profits of kr86.1m, up 46% from the prior year. Total revenue was kr2.81b over the last 12 months, up 64% from the prior year. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Karo Pharma は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測LSE:0RAQ - アナリストの将来予測と過去の財務データ ( )SEK Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数6/30/20223,466-190-2,050507N/A3/31/20223,231-141-1,546572N/A12/31/20212,961-17-290533N/A9/30/20212,92163-464377N/A6/30/20212,8612-575340N/A3/31/20212,80249-350373N/A12/31/20202,88382-1,365329N/A9/30/20202,81186-1,410214N/A6/30/20202,57587-1,56165N/A3/31/20202,27455-9525N/A12/31/20191,9019122107N/A9/30/20191,71560107146N/A6/30/20191,667117353385N/A3/31/20191,769650343368N/A12/31/20181,615657299318N/A9/30/20181,391595252261N/A6/30/20181,1325518292N/A3/31/2018785403140N/A12/31/2017658152634N/A9/30/20175151416872N/A6/30/20174631337684N/A3/31/2017404114-1060N/A12/31/201634796-106-36N/A9/30/2016308-20-119-51N/A6/30/2016232-41-125-62N/A3/31/2016151-60N/A-94N/A12/31/201569-78N/A-52N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: 0RAQの予測収益成長が 貯蓄率 ( 1% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: 0RAQの収益がUK市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: 0RAQの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: 0RAQの収益がUK市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: 0RAQの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: 0RAQの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2022/11/25 21:09終値2022/11/24 00:00収益2022/06/30年間収益2021/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Karo Pharma AB (publ) これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。3 アナリスト機関Camilla OxhamreCarnegie Investment Bank ABOlle SjölinNordea MarketsPeter AbelinRedeye
Reported Earnings • Feb 26Full year 2021 earnings: EPS in line with expectations, revenues disappointFull year 2021 results: kr0.08 loss per share (down from kr0.37 profit in FY 2020). Revenue: kr2.96b (up 2.7% from FY 2020). Net loss: kr17.5m (down 121% from profit in FY 2020). Revenue missed analyst estimates by 2.3%. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 131 percentage points per year, which is a significant difference in performance.
Reported Earnings • Oct 30Third quarter 2021 earnings released: EPS kr0.26 (vs kr0.013 loss in 3Q 2020)The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: kr738.5m (up 8.7% from 3Q 2020). Net income: kr59.0m (up kr61.8m from 3Q 2020). Profit margin: 8.0% (up from net loss in 3Q 2020). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 128 percentage points per year, which is a significant difference in performance.
Reported Earnings • Jul 23Second quarter 2021 earnings released: kr0.095 loss per share (vs kr0.11 profit in 2Q 2020)The company reported a soft second quarter result with weaker earnings and weaker control over costs, although revenues improved. Second quarter 2021 results: Revenue: kr747.9m (up 8.6% from 2Q 2020). Net loss: kr21.4m (down 184% from profit in 2Q 2020). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 127 percentage points per year, which is a significant difference in performance.
Executive Departure • Apr 27Independent Chairman of the Board Bo Hansen has left the companyOn the 21st of April, Bo Hansen's tenure as Independent Chairman of the Board ended after 2.2 years in the role. We don't have any record of a personal shareholding under Bo's name. A total of 2 executives have left over the last 12 months.
Reported Earnings • Apr 24First quarter 2021 earnings released: EPS kr0.24 (vs kr0.39 in 1Q 2020)The company reported a poor first quarter result with weaker earnings, revenues and profit margins. First quarter 2021 results: Revenue: kr713.0m (down 10% from 1Q 2020). Net income: kr53.3m (down 39% from 1Q 2020). Profit margin: 7.5% (down from 11% in 1Q 2020). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 103 percentage points per year, which is a significant difference in performance.
Reported Earnings • Apr 01Full year 2020 earnings released: EPS kr0.37 (vs kr0.051 in FY 2019)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: kr2.88b (up 52% from FY 2019). Net income: kr82.0m (up kr73.2m from FY 2019). Profit margin: 2.8% (up from 0.5% in FY 2019). Over the last 3 years on average, earnings per share has fallen by 59% per year but the company’s share price has increased by 17% per year, which means it is well ahead of earnings.
Reported Earnings • Feb 20Full year 2020 earnings released: EPS kr0.37 (vs kr0.051 in FY 2019)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: kr2.88b (up 52% from FY 2019). Net income: kr82.0m (up kr73.2m from FY 2019). Profit margin: 2.8% (up from 0.5% in FY 2019). Over the last 3 years on average, earnings per share has fallen by 59% per year but the company’s share price has increased by 16% per year, which means it is well ahead of earnings.
Is New 90 Day High Low • Feb 11New 90-day low: kr47.48The company is down 25% from its price of kr62.90 on 13 November 2020. The British market is up 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 13% over the same period.
Is New 90 Day High Low • Jan 26New 90-day low: kr48.75The company is down 26% from its price of kr66.20 on 28 October 2020. The British market is up 16% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 1.0% over the same period.
Is New 90 Day High Low • Jan 07New 90-day low: kr51.15The company is down 27% from its price of kr70.50 on 09 October 2020. The British market is up 14% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 6.0% over the same period.
Is New 90 Day High Low • Dec 18New 90-day low: kr56.30The company is down 23% from its price of kr73.10 on 18 September 2020. The British market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 12% over the same period.
Is New 90 Day High Low • Nov 26New 90-day low: kr61.20The company is down 1.0% from its price of kr61.90 on 28 August 2020. The British market is up 7.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Pharmaceuticals industry, which is down 5.0% over the same period.
Reported Earnings • Oct 30Third quarter earnings releasedOver the last 12 months the company has reported total profits of kr86.1m, up 46% from the prior year. Total revenue was kr2.81b over the last 12 months, up 64% from the prior year.